Climb Bio
Biotechnology company focused on discovering and developing monoclonal antibody therapeutics for immune-mediated and rare diseases. The organization advances investigational biologics through preclinical and clinical development, sponsors clinical studies across multiple disease areas, and maintains functions for CMC, quality, regulatory affairs, clinical operations, and corporate development.
Industries
Nr. of Employees
small (1-50)
Climb Bio
Patents
Products
Investigational monoclonal antibody therapeutics
Pipeline of investigational monoclonal antibody therapies targeting immune-mediated diseases and conditions with limited therapeutic options.
Budoprutug
Budoprutug is a highly potent, Fc-enhanced anti-CD19 monoclonal antibody designed to result in potent and durable B cell depletion, with options for both intravenous (IV) and subcutaneous (SC) administration.
Budoprutug IV
An anti-CD19 monoclonal antibody in clinical development for immune-mediated diseases.
Budoprutug SC
A subcutaneous formulation of anti-CD19 monoclonal antibody for autoimmune diseases.
CLYM116
A novel anti-APRIL monoclonal antibody featuring a sweeper mechanism designed to promote potent degradation of APRIL and extend half-life for the treatment of IgA nephropathy and other B cell-mediated diseases.
Investigational monoclonal antibody therapeutics
Pipeline of investigational monoclonal antibody therapies targeting immune-mediated diseases and conditions with limited therapeutic options.
Budoprutug
Budoprutug is a highly potent, Fc-enhanced anti-CD19 monoclonal antibody designed to result in potent and durable B cell depletion, with options for both intravenous (IV) and subcutaneous (SC) administration.
Budoprutug IV
An anti-CD19 monoclonal antibody in clinical development for immune-mediated diseases.
Budoprutug SC
A subcutaneous formulation of anti-CD19 monoclonal antibody for autoimmune diseases.
CLYM116
A novel anti-APRIL monoclonal antibody featuring a sweeper mechanism designed to promote potent degradation of APRIL and extend half-life for the treatment of IgA nephropathy and other B cell-mediated diseases.
Services
Sponsorship and operational conduct of clinical studies to evaluate investigational therapies across multiple disease areas and phases.
Development of regulatory strategy and preparation of regulatory inputs spanning nonclinical, CMC, clinical and post-marketing considerations.
Implementation and oversight of quality management systems including GMP/GLP/GCP compliance and product testing frameworks to support clinical development.
Sponsorship and operational conduct of clinical studies to evaluate investigational therapies across multiple disease areas and phases.
Development of regulatory strategy and preparation of regulatory inputs spanning nonclinical, CMC, clinical and post-marketing considerations.
Implementation and oversight of quality management systems including GMP/GLP/GCP compliance and product testing frameworks to support clinical development.
Expertise Areas
- Monoclonal antibody development
- Clinical trial management
- CMC and process development
- Regulatory affairs and compliance
Key Technologies
- Monoclonal antibody therapeutics
- Biologics development
- CMC/process development
- GMP clinical supply
News & Updates
Press release reporting financial results for Q3 2025 and providing corporate updates.
Press release reporting financial results for Q3 2025 and providing corporate updates.